MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Motor subtype stability and cognitive profiles in early Parkinson’s disease

    N. Chia, S. Ng, X. Choi, D. Heng, S. Neo, Z. Xu, K. Tay, W. Au, E. Tan, L. Tan (Singapore, Singapore)

    Objective: To examine the association between motor subtypes’ stability and cognitive assessment scores across three years in early Parkinson’s disease (PD). Background: Past studies have…
  • 2023 International Congress

    Exploring the effects of torsinA dysfunction in an iPSC-derived neuronal model of TOR1A dystonia

    S. Wrigley, N. Seto-Salvia, R. Brownstone, T. Warner (London, United Kingdom)

    Objective: To investigate phenotypic differences between iPSC-differentiated cortical neurons derived from patients with TOR1A dystonia compared to healthy controls. Background: Primary generalised dystonia is most…
  • 2023 International Congress

    Long-term follow up of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration Syndrome: two case reports

    D. Damas, I. Carvalho, S. Caldeira, P. Monteiro, R. Pereira, I. Cunha, F. Moreira (Coimbra, Portugal)

    Objective: To present the long-term outcomes of deep brain stimulation in two cases of Pantothenate kinase-associated neurodegeneration (PKAN) syndrome. Background: PKAN syndrome is an autosomal-recessive…
  • 2023 International Congress

    Longitudinal association of mild behavioral impairment with cognitive decline in Parkinson’s disease

    G. Pinilla-Monsalve, M. Kibreab, N. Maarouf, I. Kathol, Z. Ismail, O. Monchi (Montréal, Canada)

    Objective: To analyze the cross-sectional and longitudinal association between mild behavioral impairment and cognitive impairment in Parkinson’s disease. Background: Cognitive impairment and neuropsychiatric symptoms (NPS)…
  • 2023 International Congress

    The effect of dopaminergic medication on force fluctuation in Parkinson’s disease

    B. Afsharipour, M. Schindle, F. Roy, F. Ba, M. Gorassini, T. Sankar (Edmonton, Canada)

    Objective: To quantify and compare muscle force variability during isometric dorsiflexion in male patients with Parkinson's Disease (PD), in the ON- versus OFF-medication state. Background:…
  • 2023 International Congress

    Hearing impairment and non-motor symptoms in Parkinson’s disease: association and impact on quality of life

    E. Garasto, M. Conti, A. Viziano, A. Stefani, M. Pierantozzi, NB. Mercuri, A. Moleti, R. Sisto, T. Schirinzi, R. Cerroni (Rome, Italy)

    Objective: The aim of the study was to investigate the possible correlation between non-motor symptoms (NMS) burden and quality of life (QoL) with hearing impairment…
  • 2023 International Congress

    Individual-specific brain functional connectivity mapping of therapeutic response in task-specific focal dystonia

    E. Gordon, K. Matthews, A. Meyer, S. Norris (St. Louis, USA)

    Objective: Determine therapeutic effects of botulinum toxin on functional connectivity in individuals with task-specific dystonia. Background: Isolated task-specific dystonia occurs during specific activities, but not…
  • 2023 International Congress

    Dystonia in the Middle East – The Cleveland Clinic Abu Dhabi Experience

    S. Mansoor, K. Waqar, M. Thomas, S. Mittal (Abu Dhabi, United Arab Emirates)

    Objective: This study aimed to evaluate the clinical spectrum of patients with dystonia seen at Cleveland Clinic Abu Dhabi Hospital (CCAD), a tertiary care center…
  • 2023 International Congress

    Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study

    J. Aldred, A. Amelin, A. Antonini, B. Bergmans, F. Bergquist, M. Bouchard, K. Budur, C. Carroll, K. Chaudhuri, S. Criswell, E. Danielsen, E. Freire Alvarez, F. Gandor, J. Jia, T. Kimber, H. Mochizuki, W. Robieson, A. Spiegel, D. Standaert, S. Talapala, M. Facheris, V. Fung (Spokane, USA)

    Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…
  • 2023 International Congress

    An in-vivo study of regional synaptic density loss in patients with Multiple System Atrophy using [11C]UCB-J PET molecular imaging.

    E. de Natale, A. Terry, H. Wilson, J. Verghese, G. Pagano, P. Khosropanah, M. Howard, H. Wright, L. Cashmore, L. Passamonti, M. Hutchison, K. Evans, Y. Lewis, E. Rabiner, M. Politis (London, United Kingdom)

    Objective: We present preliminary, cross-sectional data, on the in-vivo evaluation of pre-synaptic terminal density in the brain of patients with Multiple System Atrophy (MSA) compared…
  • « Previous Page
  • 1
  • …
  • 580
  • 581
  • 582
  • 583
  • 584
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley